From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC). Depatuxizumab mafodotin specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used in the study of glioma, head and neck squamous cellcarcinoma, non-small celllung cancer, epidermoid carcinoma of the skin, and squamous cellcarcinoma of the tongue .
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small celllung cancer, esophageal squamous cellcarcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum . Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small celllungcarcinoma A549 cell inhibitory activity .
PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor, with IC50 of 1 μM. PLK1-IN-11 can be used in research on a variety of cancers, including pancreatic, ovarian, breast, and non-small celllungcarcinoma .
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small celllung cancer (NSCLC) and melanoma .
Mitumomab is an anti-idiotypic mouse IgG2b monoclonal antibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-celllungcarcinoma .
DDR1-IN-10 (compound 7q) is a DDR1 inhibitor. DDR1-IN-10 can be used in the study of pancreatic cancer, non-small celllung cancer, and gastric carcinoma .
SMARCA2-IN-10 (Compound 4) is a highly selective SMARCA2 ATPase domain inhibitor (IC50=17.676 μM). SMARCA2-IN-10 induces cell death in SMARCA4-deficient tumors. SMARCA2-IN-10 is promising for research of SMARCA4-mutant non-small celllung cancer, small cell ovarian carcinoma, and melanoma .
Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small celllung cancer and hepatocellular carcinoma .
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small celllung cancer (NSCLC), colorectal cancer (CRC), and squamous cellcarcinoma of the head and neck (SCCHN) .
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small celllung cancer and hepatocellular carcinoma .
HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cellcarcinomacells to vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cellcarcinoma, gastric cancer, metastatic breast cancer, small celllung cancer, and other solid tumors .
KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC50 value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small celllungcarcinomas (NSCLC) .
EML4-ALK is a fusion-type protein tyrosine kinase produced through gene rearrangement. EML4-ALK is a potential molecular target in non-small celllungcarcinoma (NSCLC). EML4 ALK Recombinant Human Active Protein Kinase is a recombinant EML4 ALK protein that can be used to study EML4 ALK-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small celllungcarcinoma (NSCLC). ALK has multiple mutants. ALK L1196M Recombinant Human Active Protein Kinase is a recombinant ALK L1196M protein that can be used to study ALK L1196M-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small celllungcarcinoma (NSCLC). ALK has multiple mutants. ALK F1174S Recombinant Human Active Protein Kinase is a recombinant ALK F1174S protein that can be used to study ALK F1174S-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small celllungcarcinoma (NSCLC). ALK has multiple mutants. ALK C1156Y Recombinant Human Active Protein Kinase is a recombinant ALK C1156Y protein that can be used to study ALK C1156Y-related functions .
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small celllungcarcinoma (NSCLC). ALK has multiple mutants. ALK G1202R Recombinant Human Active Protein Kinase is a recombinant ALK G1202R protein that can be used to study ALK G1202R-related functions .
Chloroxoquinoline is an anticancer agent. Chloroxoquinoline damages the DNA templates of cancer cells, inducing DNA breaks and cell death, and inhibits cell invasion via down-regulating Rho/Rho kinase signaling pathway. Chloroxoquinoline enhances the radiation sensitivity of Lewis lung cancer cells and xenograft tumors in tumor-bearing mouse models but decreases efficacy after long term exposure in rat models by auto-induction effects on CYP1A and CYP3A. Chloroxoquinoline has a broad-spectrum anticancer activity, such as non-small-celllungcarcinoma (NSCLC), breast cancer and gastric cancer .
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a Ki of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-celllungcarcinoma (NSCLC) .
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cellcarcinoma (ESCC), non-small celllung cancer (NSCLC) and gastric cancer .
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small celllung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cellcarcinoma (ESCC), non-small celllung cancer (NSCLC) and gastric cancer .
Apoptosis inducer 43 is an apoptosis inducer. Apoptosis inducer 43 can induce apoptosis, SubG0-G1 cell cycle arrest, secondary necrosis, and upregulate caspase-3, p53, and Bax/Bcl-2 expression in HCT116 cells. Apoptosis inducer 43 can inhibit tumor growth in a solid Ehrlich carcinoma (SEC) mouse model. Apoptosis inducer 43 can be used to study cancers such as colon cancer, leukemia, and non-small celllung cancer .
Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cellcarcinoma (ESCC), non-small celllung cancer (NSCLC) and gastric cancer .
Alveltamig (ZG006) is a trispecific anti-T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3. Alveltamig has two distinct DLL3 epitopes, and bridges tumor cells and T cells by strongly binding to DLL3 on tumor cells and CD3 on T cells, thereby mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the study of small celllung cancer (SCLC) or neuroendocrine carcinoma (NEC) .
Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cellcarcinoma (ESCC), non-small celllung cancer (NSCLC) and gastric cancer .
Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cellcarcinoma (ESCC), non-small celllung cancer (NSCLC) and gastric cancer .
EML4-ALK is a fusion-type protein tyrosine kinase produced through gene rearrangement. EML4-ALK can be used for the study of non-small celllungcarcinoma (NSCLC) and neuroblastoma (NB). EML4-ALK has multiple mutants. EML4 ALK F1174L Recombinant Human Active Protein Kinase is a recombinant EML4 ALK F1174L protein that can be used to study EML4 ALK F1174L-related functions .
HsClpP activator-2 is an orally active HsClpP agonist with a KD of 40 nM. HsClpP activator-2 potently inhibits SCLC cells including H69 (IC50 = 0.17 μM) and H82 (IC50 = 0.19 μM). HsClpP activator-2 disrupts mitochondrial membrane potential (MMP), as well as induces apoptosis and ROS in H82 cells. HsClpP activator-2 significantly inhibits tumor growth in non-SMC xenograft models with a tumor growth inhibition. HsClpP activator-2 can be used for the study of small celllungcarcinoma (SCLC) .
Afatinib (dimaleate) (Standard) is the analytical standard of Afatinib (dimaleate). This product is intended for research and analytical applications. Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cellcarcinoma (ESCC), non-small celllung cancer (NSCLC) and gastric cancer .
EGFR-IN-1671 is a selective EGFR inhibitor with an IC50 of 0.19 nM. EGFR-IN-167 exhibits good potency against various EGFR mutants (IC50 = 0.109 nM, 0.75 nM and <0.05 nM against EGFR (L858R), EGFR (C797S) and EGFR (del19), respectively). EGFR-IN-1671 covalently engages the catalytically conserved lysine of EGFR in live mammalian cells. EGFR-IN-1671 demonstrates excellent anti-proliferative activity by inhibiting EGFR autophosphorylation. EGFR-IN-1671 can be used for the study of non-small-celllungcarcinomas (NSCLC), glioblastoma and many solid tumors .
(R)-Afatinib ((R)-BIBW 2992) is the Afatinib isomer. Afatinib (HY-10261) is an orally active, potent and irreversible dual specificity inhibitor of?ErbB?family (EGFR?and?HER2), with?IC50?values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for?EGFR wt, EGFR L858R,?EGFR L858R/T790M?and HER2, respectively. Afatinib can be used for the research of esophageal squamous cellcarcinoma (ESCC), non-small celllung?cancer?(NSCLC) and gastric?cancer .
EGFR-IN-165 is a potent EGFR inhibitor. EGFR-IN-165 demonstrates superior potency with IC50s of 17.18 and 64.74 nM against EGFR L858R/T790M and EGFR WT; 2.17 and 6.2 μM against NCI-H1975 cells and A431 cells. EGFR-IN-165 significantly inhibits the migration and induces G1 phase cell cycle arrest and cellapoptosis. EGFR-IN-165 can be used for the study of cancers such as non-small celllung cancer, colorectal cancer, and head and neck squamous cellcarcinoma .
Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC50 of 2.5 μM), but no inhibitory effect on HDAC4 (IC50>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small celllungcarcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis .
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small celllung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small celllung cancer, esophageal squamous cellcarcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small celllung cancer (NSCLC) and melanoma .
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small celllung cancer and hepatocellular carcinoma .
Mitumomab is an anti-idiotypic mouse IgG2b monoclonal antibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-celllungcarcinoma .
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small celllung cancer (NSCLC), colorectal cancer (CRC), and squamous cellcarcinoma of the head and neck (SCCHN) .
Alveltamig (ZG006) is a trispecific anti-T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3. Alveltamig has two distinct DLL3 epitopes, and bridges tumor cells and T cells by strongly binding to DLL3 on tumor cells and CD3 on T cells, thereby mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the study of small celllung cancer (SCLC) or neuroendocrine carcinoma (NEC) .
Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum . Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small celllungcarcinoma A549 cell inhibitory activity .
Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cellcarcinoma (ESCC), non-small celllung cancer (NSCLC) and gastric cancer .
The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (HEK293, Fc) is the recombinant human-derived CD24 protein, expressed by HEK293 , with C-hFc labeled tag.
The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (S44T, HEK293, Fc) is the recombinant human-derived CD24 protein, expressed by HEK293 , with C-hFc labeled tag and S44T, , , , mutation.
The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived CD24 protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.
The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (HEK293, His) is the recombinant human-derived CD24 protein, expressed by HEK293, with C-His labeled tag.
The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (HEK293, His) is the recombinant human-derived CD24 protein, expressed by HEK293 , with N-6*His labeled tag.
The CD24 protein plays a critical role in cellular differentiation in various cell types, and its signaling may be initiated by lectin-like ligands that bind to the CD24 carbohydrate and transduced by second messengers released from GPI anchors. CD24 also regulates B cell activation responses, promoting AG-dependent B cell proliferation and preventing terminal differentiation into antibody-forming cells. CD24 Protein, Human (HEK293, His, Ferritin) is the recombinant human-derived CD24 protein, expressed by HEK293, with N-His labeled tag.
